Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Joao M Victor Alessi"'
Autor:
Yuan Chen, Biagio Ricciuti, Matthew D Hellmann, Hira Rizvi, Mark M Awad, Giuseppe Lamberti, Arielle Elkrief, Jamie E Chaft, Xinan Wang, Samantha Brown, Charles M Rudin, Joao M Victor Alessi, Isabel R Preeshagul, Federica Pecci, Alessandro Di Federico, Jacklynn V Egger, Gregory J Riely, Mark G Kris, Marc Ladanyi, Ronglai Shen, Adam J Schoenfeld
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 7 (2023)
Background Single-agent PD-(L)1 blockade (IO) alone or in combination with chemotherapy (Chemotherapy-IO) is approved first-line therapies in patients with advanced lung adenocarcinomas (LUADs) with PD-L1 expression ≥1%. These regimens have not bee
Externí odkaz:
https://doaj.org/article/1db67c48820e42a9b021621d9022be62
Autor:
Arielle Elkrief, Joao M. Victor Alessi, Biagio Ricciuti, Samantha Brown, Hira Rizvi, Isabel R. Preeshagul, Xinan Wang, Federica Pecci, Alessandro Di Federico, Giuseppe Lamberti, Jacklynn V. Egger, Jamie E. Chaft, Charles M. Rudin, Gregory J. Riely, Mark G. Kris, Marc Ladanyi, Yuan Chen, Matthew D. Hellmann, Ronglai Shen, Mark M. Awad, Adam J. Schoenfeld
BackgroundSingle-agent PD-(L)1 blockade (IO) alone or in combination with chemotherapy (Chemotherapy-IO) are approved first-line therapies in patients with advanced lung adenocarcinomas (LUADs) with PD-L1 expression ≥1%. These regimens have not bee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30c85e98d59b4b22ed461b9277fb1c80
https://doi.org/10.1101/2022.12.05.22283131
https://doi.org/10.1101/2022.12.05.22283131
